KeyBanc maintains Avanos Medical [AVNS]’s rating to Overweight and price target at 55
KeyBanc maintained its Avanos Medical [AVNS] rating to the equivalent of Overweight but changed the price target to $55 from $47, in a research note dated 2021-01-08. That figure represents around a 13.05% premium from where the company’s shares closed on Thursday. Other analysts also revised their coverage, with Stifel’s analysts downgrading the shares from […]
